Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2025 08:00 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, today announced the...
September 15, 2025 08:00 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

HIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced that the company will present information on two of...
September 03, 2025 16:57 ET | Source: vTv Therapeutics Inc.

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential...
September 02, 2025 08:00 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Proceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of...
August 12, 2025 16:15 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

• First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026 • Cadisegliatin intellectual...
August 11, 2025 08:00 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential...
August 07, 2025 08:00 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

HIGH POINT, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead...
June 11, 2025 08:00 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential...
May 19, 2025 09:00 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as...
May 15, 2025 16:01 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 ...